| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 07/20/2006 | CA2593274A1 Glycine reuptake inhibitors for treating drug and alcohol dependence |
| 07/20/2006 | CA2593268A1 Macrocyclic compounds useful as bace inhibitors |
| 07/20/2006 | CA2593156A1 Heterocyclic carboxamide compounds as steroid nuclear receptors ligands |
| 07/20/2006 | CA2592723A1 4- (1h-indol-3-yl) -pyrimidin-2-ylamine derivates and their use in therapy |
| 07/20/2006 | CA2592611A1 2-(cyclic aminocarbonyl)indoline derivative and medicinal composition containing the same |
| 07/20/2006 | CA2592457A1 Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors |
| 07/20/2006 | CA2591487A1 Polymorphs of memantine hydrochloride |
| 07/20/2006 | CA2590898A1 3,4,(5)-substituted tetrahvdropyridines |
| 07/20/2006 | CA2590664A1 Macrocyclic compounds and compositions useful as bace inhibitors |
| 07/20/2006 | CA2589019A1 Erythromycin derivatives as antibacterial agents |
| 07/20/2006 | CA2588925A1 Solid preparation comprising reduced coenzyme q10 and process for production of the same |
| 07/20/2006 | CA2585748A1 Dry eye emulsion |
| 07/20/2006 | CA2567601A1 Production and use of a gaseous vapor disinfectant |
| 07/20/2006 | CA2562763A1 Transcription factor modulating compounds and methods of use thereof |
| 07/20/2006 | CA2562224A1 Nucleoside derivatives for treating hepatitis c virus infection |
| 07/20/2006 | CA2493947A1 Arthro gel and syner gel |
| 07/19/2006 | EP1681355A1 Sequence-specific DNA recombination in eukaryotic cells |
| 07/19/2006 | EP1681354A2 Recombinant viruses coding for a glutamate decarboxylase (gad) |
| 07/19/2006 | EP1681304A2 Recombinant fusion proteins of growth hormone and serum albumin |
| 07/19/2006 | EP1681297A1 Tyrosinase activity inhibitor and ameliorant for facial blood flow |
| 07/19/2006 | EP1681296A1 Epimeredi glycoside a, the formulation containing thereof and their preparation method |
| 07/19/2006 | EP1681292A1 3-Amino-6-aryl(or 6-heteroaryl)-thieno¬2,3-b|pyridin-2-carboxylic acid amides, pharmaceutical compositions comprising the said and their use as inhibitors of TNFalpha release |
| 07/19/2006 | EP1681290A2 Imidazole derivatives, production method thereof and use thereof |
| 07/19/2006 | EP1681289A1 Plant-origin beta3-adrenoceptor agonist and use of the same |
| 07/19/2006 | EP1681059A1 Pharmaceutical composition containing prostaglandin |
| 07/19/2006 | EP1681058A2 Pharmacologically active cns compounds |
| 07/19/2006 | EP1681057A1 Use of naloxone for treating eating disorders |
| 07/19/2006 | EP1681056A1 Process for preparing lansoprazole |
| 07/19/2006 | EP1681055A1 Pharmaceutical preparation for the treatment of elevated homocysteine level |
| 07/19/2006 | EP1681054A1 Therapeutic agent for keratoconjunctiva disorder |
| 07/19/2006 | EP1681053A1 Composition containing reduced coenzyme q |
| 07/19/2006 | EP1681052A1 Solid pharmaceutical dosage forms for reducing the bioavailability food effect |
| 07/19/2006 | EP1681051A1 Multi-layer controlled-release tablet comprising an active layer and one or more barrier layers |
| 07/19/2006 | EP1681050A1 Dispersible sustained release pharmaceutical compositions |
| 07/19/2006 | EP1680963A1 Cocoa components, edible products having enhanced polyphenol content, methods of making same and medical uses |
| 07/19/2006 | EP1680657A2 Dmbt1 as a clinical marker and uses thereof |
| 07/19/2006 | EP1680512A1 Methods and compositions for identifying therapeutic compounds |
| 07/19/2006 | EP1680472A2 Compounds for dual photodiagnosis and therapy |
| 07/19/2006 | EP1680441A1 Crystalline forms of 3-beta-amino 17-methylene androstane-6-alpha 7-beta-diol hydrochloride |
| 07/19/2006 | EP1680438A2 Amiphiphylic peptide-pna conjugates for the delivery of pna through the blood brain barrier |
| 07/19/2006 | EP1680431A1 Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors |
| 07/19/2006 | EP1680429A1 Thieno-pyridinone derivatives as kinase inhibitors |
| 07/19/2006 | EP1680428A2 Substituted indole derivatives |
| 07/19/2006 | EP1680425A1 6- [(substituted)phenyl] triazolopyrimidines as anticancer agents |
| 07/19/2006 | EP1680424A2 Heteroaryl fused pyridines, pyrazines and pyrimidines as crf1 receptor ligands |
| 07/19/2006 | EP1680423A1 Azabenzodiazepines as phosphodiesterase-4 inhibitors |
| 07/19/2006 | EP1680420A2 Compounds, compositions, and methods |
| 07/19/2006 | EP1680417A1 1-'(e)-2-(phenyl)ethenyl-4-(arylalkoxy)-oxazole or -thiazole compounds as her-2 tyrosine kinases inhibitors and their use in the treatment of cancer |
| 07/19/2006 | EP1680416A2 Naphthalene-1,5-disulfonic acid salts of a substituted 4-amino-1-(pyridylmethyl)piperidine compound |
| 07/19/2006 | EP1680415A1 Pyrrolidinyl urea derivatives as angiogenesis inhibitors |
| 07/19/2006 | EP1680414A2 Substituted indazole-o-glucosides |
| 07/19/2006 | EP1680412A1 Tocopheryl polyethylene glycol succinate articles and process for preparing tpgs articles |
| 07/19/2006 | EP1680411A2 Modulators of atp-binding cassette transporters containing cycloalkyl or pyranyl groups |
| 07/19/2006 | EP1680409A2 Ph sensitive prodrugs of 2,6-diisopropylphenol |
| 07/19/2006 | EP1680408A2 Ccr3 receptor antagonists |
| 07/19/2006 | EP1680406A1 N-substituted benzene sulfonamides |
| 07/19/2006 | EP1680401A2 Indolinone derivatives and their use in treating disease-states such as cancer |
| 07/19/2006 | EP1680398A1 Thiourea derivative-containing pharmaceutical composition having improved solubility and bioavailability |
| 07/19/2006 | EP1680396A1 Novel molecule for inducing differentiation of dendritic cells |
| 07/19/2006 | EP1680189A2 Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions |
| 07/19/2006 | EP1680144A1 Methylphenidate solution and associated methods of administration and production |
| 07/19/2006 | EP1680143A2 Treatment of arthritic conditions, chronic inflammation or pain |
| 07/19/2006 | EP1680140A2 Fibroblast growth factor receptor-1 inhibitors and methods of treatment thereof |
| 07/19/2006 | EP1680134A1 Compositions and uses therof |
| 07/19/2006 | EP1680133A2 High affinity ligands for influenza virus and methods for their production |
| 07/19/2006 | EP1680132A2 Methods of using and compositions comprising thalidomide for treatment, modification and management of fibromyalgia |
| 07/19/2006 | EP1680131A2 Substituted indole-o-glucosides |
| 07/19/2006 | EP1680130A2 Desensitization of complement activation using monocyte/macrophage inhibitory compounds |
| 07/19/2006 | EP1680129A2 Inosine monophosphate dehydrogenase inhibitors as phosphonate derivatives |
| 07/19/2006 | EP1680128A1 Myo-inositol hexaphosphate for topical use |
| 07/19/2006 | EP1680126A1 Neuroprotection with beta-lactam compounds |
| 07/19/2006 | EP1680125A1 Combination of an allosteric inhibitor of matrix metalloproteinase-13 and a ligand to an alpha-2-delta receptor |
| 07/19/2006 | EP1680124A2 Bicyclic [3.1.0] derivatives as glycine transporter inhibitors |
| 07/19/2006 | EP1680123A1 Use |
| 07/19/2006 | EP1680122A1 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for the treatment of cancer |
| 07/19/2006 | EP1680121A2 Methods and reagents for the treatment of immunoinflammatory disorders |
| 07/19/2006 | EP1680120A2 Combinations useful for the treatment of neuronal disorders |
| 07/19/2006 | EP1680119A1 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) |
| 07/19/2006 | EP1680118A1 Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer |
| 07/19/2006 | EP1680117A2 Use of a pyrazole derivative for preparing medicaments for the prevention and the treatment of dyslipidemia and illnesses associated with dyslipidemia and/or obesity |
| 07/19/2006 | EP1680116A1 Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors |
| 07/19/2006 | EP1680115A1 Use of selective opiate receptor modulators in the treatment of neuropathy |
| 07/19/2006 | EP1680114A2 Triazole compounds and uses related thereto |
| 07/19/2006 | EP1680113A2 Dopamine-, norepinephrine- and serotonin- transporter- selective heterocyclic compounds and their therapeutic applications |
| 07/19/2006 | EP1680112A2 Use of a deoxynojirimycin derivative or a pharmaceutically salt thereof |
| 07/19/2006 | EP1680111A2 Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
| 07/19/2006 | EP1680110A1 Once daily dosage forms of trospium |
| 07/19/2006 | EP1680109A1 Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same |
| 07/19/2006 | EP1680108A1 Pyridothiophene compounds |
| 07/19/2006 | EP1680106A1 Combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity and lipase inhibitors |
| 07/19/2006 | EP1680105A2 Use of glucosidase inhibitors for therapy of mucovisidosis |
| 07/19/2006 | EP1680104A1 Composition for treatment of osteoarthritis containing apigenin as chindroregenerative agent |
| 07/19/2006 | EP1680103A1 Acid containing oxaliplatin formulations |
| 07/19/2006 | EP1680102A2 Combinations of a cholesterol biosynthesis inhibitor and a soluble fiber for the treatment of conditions associated with elevated cholesterol levels |
| 07/19/2006 | EP1680100A1 Compositions of quaternary ammonium containing bioavailability enhancers |
| 07/19/2006 | EP1680099A2 Hdl-boosting combination therapy complexes |
| 07/19/2006 | EP1680098A1 Sustained release of positively charged pharmacologically active molecules from a matrix containing polymers with polarized oxygen atoms |
| 07/19/2006 | EP1680096A1 New formulation for retinoid-containing soft gelatin capsules |
| 07/19/2006 | EP1680095A2 Valsartan containing formulation |
| 07/19/2006 | EP1680094A1 Controlled release formulations of opioid and nonopioid analgesics |